Perrigo Company plc - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on Perrigo Company plc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Perrigo Company plc in the form of a SWOT analysis
An in-depth view of the business model of Perrigo Company plc including a breakdown and examination of key business segments
Intelligence on Perrigo Company plc’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about Perrigo Company plc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Perrigo Company plc (New Perrigo or 'the company'), formerly Perrigo Company Limited, is engaged in the development, manufacture and distribution of over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients, and medical diagnostic products. It also receives royalties on sales of Tysabri, a multiple sclerosis drug. The company primarily operates in the US, Israel, Mexico, Australia and the UK. It is headquartered in Dublin, Ireland, and had 9,900 full-time and temporary employees as of August 09, 2013. Perrigo Company Limited recorded revenues of $3,539.8 million during the financial year ended June 2013 (FY2013), an increase of 11.6% over FY2012. The operating profit of the company was $679.1 million in FY2013, an increase of 19.3% over FY2012. The net profit was $441.9 million in FY2013, an increase of 10% over FY2012. Perrigo Company Limited changed its name to Perrigo Company plc and shifted its headquarters to Ireland following the completion of its acquisition of Elan Corporation Plc, an Ireland-based biotechnology company, in December 2013.
Reasons to Purchase:
Gain understanding of Perrigo Company plc and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess Perrigo Company plc as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on Perrigo Company plc’s business structure, strategy and prospects